These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases. Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628 [TBL] [Abstract][Full Text] [Related]
27. Huntingtin aggregation and toxicity in Huntington's disease. Bates G Lancet; 2003 May; 361(9369):1642-4. PubMed ID: 12747895 [TBL] [Abstract][Full Text] [Related]
28. The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation. Chaari A; Eliezer D; Ladjimi M Int J Biol Macromol; 2016 Feb; 83():433-41. PubMed ID: 26601760 [TBL] [Abstract][Full Text] [Related]
29. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance. Li X; Liu H; Fischhaber PL; Tang TS Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252 [TBL] [Abstract][Full Text] [Related]
30. [Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1]. Nagai Y; Nukina N Rinsho Shinkeigaku; 2011 Nov; 51(11):1108-10. PubMed ID: 22277499 [TBL] [Abstract][Full Text] [Related]
31. Ubiquitin conjugating enzymes participate in polyglutamine protein aggregation. Howard RA; Sharma P; Hajjar C; Caldwell KA; Caldwell GA; du Breuil R; Moore R; Boyd L BMC Cell Biol; 2007 Jul; 8():32. PubMed ID: 17663792 [TBL] [Abstract][Full Text] [Related]
32. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Wang H; Lim PJ; Yin C; Rieckher M; Vogel BE; Monteiro MJ Hum Mol Genet; 2006 Mar; 15(6):1025-41. PubMed ID: 16461334 [TBL] [Abstract][Full Text] [Related]
33. A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Brehme M; Voisine C; Rolland T; Wachi S; Soper JH; Zhu Y; Orton K; Villella A; Garza D; Vidal M; Ge H; Morimoto RI Cell Rep; 2014 Nov; 9(3):1135-50. PubMed ID: 25437566 [TBL] [Abstract][Full Text] [Related]
34. Chaperone-like activity of high-mobility group box 1 protein and its role in reducing the formation of polyglutamine aggregates. Min HJ; Ko EA; Wu J; Kim ES; Kwon MK; Kwak MS; Choi JE; Lee JE; Shin JS J Immunol; 2013 Feb; 190(4):1797-806. PubMed ID: 23303669 [TBL] [Abstract][Full Text] [Related]
35. Co-chaperone CHIP promotes aggregation of ataxin-1. Choi JY; Ryu JH; Kim HS; Park SG; Bae KH; Kang S; Myung PK; Cho S; Park BC; Lee DH Mol Cell Neurosci; 2007 Jan; 34(1):69-79. PubMed ID: 17127076 [TBL] [Abstract][Full Text] [Related]
37. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins. Saunders HM; Bottomley SP Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877 [TBL] [Abstract][Full Text] [Related]
38. Effects of chain length on the aggregation of model polyglutamine peptides: molecular dynamics simulations. Marchut AJ; Hall CK Proteins; 2007 Jan; 66(1):96-109. PubMed ID: 17068817 [TBL] [Abstract][Full Text] [Related]
39. Protein-misfolding diseases and chaperone-based therapeutic approaches. Chaudhuri TK; Paul S FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923 [TBL] [Abstract][Full Text] [Related]
40. The potential of indole and a synthetic derivative for polyQ aggregation reduction by enhancement of the chaperone and autophagy systems. Lin CH; Wu YR; Kung PJ; Chen WL; Lee LC; Lin TH; Chao CY; Chen CM; Chang KH; Janreddy D; Lee-Chen GJ; Yao CF ACS Chem Neurosci; 2014 Oct; 5(10):1063-74. PubMed ID: 25197952 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]